KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Net Cash Flow (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Net Cash Flow data on record, last reported at -$2.0 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 189.08% year-over-year to -$2.0 million; the TTM value through Sep 2025 reached $10.9 million, up 131.29%, while the annual FY2024 figure was $9.0 million, 116.94% up from the prior year.
  • Net Cash Flow reached -$2.0 million in Q3 2025 per NKTR's latest filing, down from $4.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $42.8 million in Q1 2022 and bottomed at -$98.3 million in Q3 2021.
  • Average Net Cash Flow over 5 years is -$8.3 million, with a median of -$2.0 million recorded in 2025.
  • Peak YoY movement for Net Cash Flow: plummeted 3870.23% in 2021, then skyrocketed 333.81% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$28.8 million in 2021, then skyrocketed by 38.91% to -$17.6 million in 2022, then plummeted by 68.61% to -$29.7 million in 2023, then skyrocketed by 147.59% to $14.1 million in 2024, then crashed by 113.87% to -$2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$2.0 million in Q3 2025, $4.1 million in Q2 2025, and -$5.4 million in Q1 2025.